Kazia Theraputics Limited Annual Report 2023 1 The past year has been significant for Kazia Therapeutics, with considerable progress being made across our clinical programs and as a business. We have completed a full portfolio review and we will streamline the paxalisib clinical development program into three pillars; adult brain cancer, paediatric brain cancer and brain metastases. As targeted therapeutics, both paxalisib and EVT801 have the potential to benefit many patients around the world with PI3K pathways and VEGFR3 mutations respectively. kaziatherapeutics.com Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports
RkJQdWJsaXNoZXIy MjE2NDg3